Dianthus Therapeutics announces positive data for Claseprubart (DNTH103) from the Phase 2 MaGic trial in Generalized Myasthenia Gravis.
Claseprubart demonstrated statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13.
Both 300mg and 600mg doses of Claseprubart showed rapid onset of action and were well-tolerated with a favorable safety profile.
Positive Trial Results
Both Claseprubart 300mg and 600mg doses achieved significant improvements in key efficacy endpoints, supporting its best-in-class profile.
Safety Profile
Claseprubart demonstrated a favorable safety profile with no related serious adverse events, aligning with the product's target profile.
Upcoming Phase 3 Trial
A Phase 3 trial evaluating Claseprubart's efficacy against placebo is expected to start in 2026.
- The results from the Phase 2 MaGic trial highlight the potential of Claseprubart as a promising treatment option for Generalized Myasthenia Gravis patients.
- The positive outcomes support Dianthus Therapeutics' strategy of advancing antibody complement therapeutics to address severe autoimmune diseases.
The successful Phase 2 trial results reinforce Claseprubart's efficacy and safety profile, paving the way for further clinical advancements and potential market approval.